Elad: Can Chameleon Cloud and LayerX Really Change the Mix?
Chameleon’s cloud shift and the launch of LayerX are real strategic moves, backed by a strong installed base and already-live SaaS customers. But in 2025 this layer is still too small, and still too noisy in the reported numbers, to change Elad’s economics on its own while the group remains fundamentally service and labor led.
What This Follow-up Is Testing
The main article’s core argument was that Elad’s AI story is interesting, but the group’s actual economics still sit in services, implementation work and human capital. This follow-up isolates the one place where management is genuinely trying to alter that equation: Chameleon in the cloud and LayerX.
The positive side is that this is not just slideware. From the second half of 2025, Chameleon has also been offered as a SaaS product, some customers have already upgraded and are running it in production, and LayerX is meant to connect AI capabilities and third-party solutions into the medical record in a simple and secure way. That is exactly the kind of layer Elad needs if it wants to move from project hours and implementation work toward more recurring and product-like economics.
But 2025 still does not prove that this has already happened at group level. The health activity still sits inside the non-reportable "Others" bucket, and that bucket generated only NIS 26.4 million of revenue in 2025, less than 5% of consolidated sales. Even after a sharp profitability improvement, it contributed NIS 8.1 million of segment profit, only about 9.4% of group gross profit. This is no longer a side note, but it is also not yet an engine that changes Elad as a whole.
| What supports the shift | What still blocks it |
|---|---|
| Chameleon has an unusually strong installed base, around 80% of Israeli hospitals, about 45 medical centers, more than 1,000 clinical units and roughly 65 thousand active users | The activity is still too small at group level and still does not qualify as a standalone reportable segment |
| From the second half of 2025 there are already customers running the SaaS version in production | The reported "Others" numbers are not a clean Elad Health measure, because they still included the training activity that was sold in April 2025 |
| LayerX is supposed to open an additional revenue channel by plugging AI and third-party solutions into Chameleon | Elad’s core still runs through IT services, outsourcing and implementation, with 1,418 of 1,532 employees in software-service roles |
| Development investment accelerated, with NIS 9.243 million of capitalized development costs in 2025 versus NIS 5.503 million in 2024 | Even after that acceleration, the investment is only about 1.7% of revenue, which is meaningful directionally but not a business-model reversal |
The Positive Signal Is Real
If the asset is judged on quality first, it is easy to see why this is the most interesting issue inside Elad. Chameleon is not another consulting layer billed through project teams. It is a clinical platform that Elad developed and fully owns, with unusually deep penetration across the Israeli hospital system. Commercially, that is a much better starting point than a product trying to enter from zero: the installed base already exists, the workflow is mission critical, and customers are already running on it every day.
That is also why the cloud move matters. When a company with this kind of installed base says some customers have already upgraded and are operating in production on the SaaS version, that is a real sign of movement rather than just roadmap language. It still does not mean recurring revenue is already large enough to reshape the group’s reported economics. It does mean the company has moved at least part of the installed base from technological promise to live product.
LayerX is the second leg of the same story. Elad describes it as a suite that connects AI capabilities and third-party solutions into Chameleon in an integrative and secure way, making the product more open to adjacent systems and advanced solutions. The key phrase here is not AI. It is an additional revenue channel. If this layer works, Elad can expand revenue per existing customer without necessarily opening a fresh heavy implementation project every time.
The investment pace also shows management is spending against the thesis. Capitalized development costs rose to NIS 9.243 million in 2025 from NIS 5.503 million in 2024, and the product-development asset reached NIS 21.524 million. At the same time, the company’s annual R&D policy stands at about 1% to 2% of revenue. That is not the profile of a pure software product company. It is enough to show that Elad is trying to build a real product layer on top of its services engine.
Why 2025 Still Does Not Prove A Mix Shift
The first and most important point is that the 2025 numbers are noisier than they first appear. The "Others" bucket is not a clean Elad Health line. Until April 2025 it also included Elad Campus, the training business that was sold as part of management’s decision to refocus on core operations after demand for open-market digital and tech courses weakened. So the jump in "Others" gross margin from 9.0% to 30.8% is a positive sign, but not clean proof that the cloud shift and LayerX already did all the work. Part of that improvement may simply reflect the removal of a weaker activity.
That is exactly why the sharp profitability improvement should not be read too quickly as productization already delivered. Revenue in "Others" actually fell 11.3% to NIS 26.4 million, while segment profit rose to NIS 8.1 million from NIS 2.7 million. Something clearly improved in quality. What is still not clear is how much of that improvement came from new monetization inside Chameleon cloud and LayerX, and how much came from cleaning up the composition of that accounting bucket.
The second point is scale. The core IT services, consulting and management segment alone generated about NIS 508.7 million of revenue in 2025 and NIS 78.1 million of segment profit. That core even saw a mild gross-margin decline, from 16.8% to 15.4%, and yet it still remained almost the whole business. So even if Chameleon cloud and LayerX are beginning to work, they are still operating inside a group whose economics are driven by projects, integration, outsourcing and labor hours.
The third point is workforce structure. At the end of 2025 the group employed 1,532 people, of whom 1,418 were in software-service roles. That is about 92.6% of the workforce. The company also explains that software-service revenue is recognized over time as the service is delivered, and it identifies the shortage of skilled technology workers as a major risk. Put simply, Elad’s core economic engine is still a delivery machine. The product layer is supposed to improve that machine, not replace it in the near term.
The analytical implication is straightforward: Chameleon and LayerX now create a better strategic option than Elad had a year ago. They still do not prove that the consolidated mix has already moved in a meaningfully more product-like direction. In 2025 this is still a transition year, not a decisive one.
What Has To Happen For The Shift To Become Material
Management itself lists three things that have to happen next year: expand LayerX inside Chameleon, move Chameleon customers to cloud architecture and subscription-based agreements, and complete the Next Generation version of the medical record. All three matter, but not at the same layer.
The first trigger is the installed base. When one system already sits across around 80% of Israeli hospitals, the real test is no longer penetration. It is migration. If Elad can move part of that installed base into subscription agreements, it starts changing the nature of revenue rather than only changing the technology stack.
The second trigger is attach rate. LayerX only becomes economically interesting if it lets Elad sell more into each existing hospital without adding delivery teams, hours and service cost in the same proportion. If every expansion still requires a heavy project cycle, then the product sits on top of the services model without truly changing its economics.
The third trigger is cleaner reporting. Once Campus is out of the comparison base, 2026 should offer a much cleaner read on Elad Health. If the "Others" bucket still improves margins, grows and gains weight after that cleanup, then it becomes reasonable to talk about a real mix shift at group level. If not, the option value may be real, but it still will not have turned into a material earnings engine.
| Test | What exists today | What would count as real proof |
|---|---|---|
| Cloud migration | There are already customers live in production on the SaaS version | Visible growth in recurring revenue and subscription-based agreements |
| LayerX monetization | The suite has launched and is meant to add AI and third-party revenue around Chameleon | Higher revenue per existing customer without a matching rise in headcount |
| Group mix change | "Others" improved sharply, but is still less than 5% of revenue | Rising revenue and profit weight, with a cleaner health read once Campus drops out of the base |
Execution Risks Around The Story
Precisely because Chameleon sits deep inside hospital workflows, the move to cloud is not as simple as upgrading a CRM system at a commercial enterprise. The company itself flags regulation, dependence on information systems, cyber risk and information security, as well as sensitivity to communication and data-system disruptions. In practice that means the cloud migration can be slow, staged and operationally heavy even if the strategic direction is right.
There is also a broader macro risk. Economic slowdown or cuts in IT budgets can delay projects, reduce demand and hurt customers’ ability to pay. In Chameleon’s case that would not necessarily break the installed base, but it can still delay upgrades, expansions and the transition into new commercial models.
And finally there is Elad’s own identity. The company still builds its value proposition around end-to-end solutions, integration work, expert services and outsourcing. That identity has commercial strength. It also makes a clean fast shift into pure product economics harder. In that sense, cloud and LayerX are not only competing with outside alternatives. They are also pushing against Elad’s own successful service habits.
Bottom Line
Chameleon cloud and LayerX are the most interesting layer inside Elad because they are the only place where the company can gain not just another project, but a real change in revenue quality. There is a strong installed base, there are already live SaaS customers, the product is opening up to AI and third-party solutions, and development investment is clearly accelerating.
But 2025 still does not stamp the shift as already proven. The relevant bucket is still too small at group level, its profitability is still affected by the Campus disposal and therefore is not yet a clean Elad Health read, and Elad’s core still runs through services and labor. So the answer to the headline question is two-sided: yes, there is now a mechanism that can change the mix. No, 2025 does not yet prove that it already has.
| Question | Short answer |
|---|---|
| Is the strategic direction real | Yes. The cloud move, the launch of LayerX and the acceleration in development investment all point to a real effort |
| Has the shift already become material in the numbers | Not yet. The relevant layer is still small, accounting-noisy and not separated as its own segment |
| What decides the next 2 to 4 quarters | Chameleon cloud migrations, subscription agreements, and whether revenue per customer can expand without the cost base scaling in lockstep |
Current thesis: Chameleon cloud and LayerX are Elad’s real upside option, but right now they are still an option with early evidence rather than an engine that replaces the group’s services economics.
Counter-thesis: The reports may still understate the shift, because the installed base is already there, some customers are already live in the cloud, and 2026 should offer a much cleaner read on the health economics once Campus is fully out of the comparison base.
Why this matters: if Elad can turn a strong installed base into subscription revenue and attach more income through LayerX, the market will start looking at it less as a delivery company and more as a platform that sells a product layer on top of existing delivery.
What has to happen next is clear: more Chameleon customers need to move into the cloud, LayerX has to show up as added revenue rather than only added capability, and the 2026 read has to become cleaner once Campus no longer distorts the comparison. If those three things arrive together, the mix can start to move for real.